The GRAIL Company in Menlo Park, California has introduced what it calls a first-of-a-kind multi-cancer early detection test called Galleri. Through advancements in genomics research and DNA sequencing, Galleri has the ability to detect more than 50 types of cancer, including malignant pleural mesothelioma, through a single blood draw.

Galleri is backed by clinical observation studies reporting that it can detect cancer signals across multiple cancer types and predict cancer origin or location with high accuracy with a false positive rate of less than 1%.

Select U.S. health systems, including Providence in California, Oregon and Washington and The Mayo Clinic, have begun to offer access to the early detection blood test, as a complement to recommended single cancer screening tests. Galleri is intended to supplement existing cancer diagnostic tests within the context of a patient’s medical history and symptoms. It’s important to note that Galleri is prescription-only and must be ordered by a licensed health-care provider. It’s currently not covered by health insurance and has an out-of-pocket cost of $949.

As with most cancers, the sooner Mesothelioma is discovered, the better the odds it can be successfully treated. This exciting breakthrough in early detection has the potential to reduce the human toll of cancer and the heartbreak that comes with a delayed diagnosis.